世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

MEA遺伝子治療市場 - 産業動向と2030年までの予測


MEA Gene Therapy Market - Industry Trends and Forecast to 2030

中東・アフリカの遺伝子治療市場は、2023年から2030年にかけて18.3%のCAGRを記録すると予測されています。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年1月3日 US$3,500
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		130 英語

　

サマリー

中東・アフリカの遺伝子治療市場は、2023年から2030年にかけて18.3%のCAGRを記録すると予測されています。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションを行います：
中東・アフリカの遺伝子治療市場、ベクタータイプ別（ウイルスベクター、非ウイルスベクター）、方法別（生体外、生体内）、用途別（腫瘍疾患、心血管疾患、感染症、希少疾患、神経疾患、その他の疾患）、エンドユーザー（がん研究所、病院、研究機関、その他）、国（南アフリカ、中東・アフリカのその他） 産業動向および2030年までの予測
遺伝子治療市場の成長に寄与する主な要因としては、以下のようなものが挙げられます：

- 個別化医療の需要の高まり
- 遺伝性疾患の有病率の上昇
- 遺伝子治療の新たなアプローチ

市場のプレーヤー：

中東・アフリカの遺伝子治療市場の主要な市場関係者は以下の通りです：

- アムジェン社（Amgen, Inc.
- アンジェス社
- バイオジェン
- ブリストル・マイヤーズ スクイブ・カンパニー
- CHIESI Farmaceutici S.p.A.
- ヤンセンファーマシューティカルズInc.
- ノバルティスAG




ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET 20
1.4 CURRENCY AND PRICING 22
1.5 LIMITATIONS 22
1.6 MARKETS COVERED 22
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.6 MULTIVARIATE MODELLING 31
2.7 MARKET END USER COVERAGE GRID 31
2.8 PRODUCT LIFELINE CURVE 32
2.9 DBMR MARKET POSITION GRID 33
2.10 VENDOR SHARE ANALYSIS 34
2.11 SECONDARY SOURCES 35
2.12 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 39
4.1 PESTEL ANALYSIS 40
4.2 PORTER FIVE ANALYSIS 41
5 UPDATE ON GERMLINE GENE THERAPY 42
5.1 GERMLINE GENE THERAPY 42
6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, MO 43
6.1 DRIVERS 45
6.1.1 NOVEL APPROACHES TO GENE THERAPY 45
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 45
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 46
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 47
6.2 RESTRAINTS 47
6.2.1 HIGH COST OF GENE THERAPY 47
6.2.2 ETHICAL AND SAFETY CONCERNS 48
6.2.3 COMPLEXITY OF GENE THERAPY 48
6.3 OPPORTUNITIES 49
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 49
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 49
6.4 CHALLENGES 50
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 50
6.4.2 LONG-TERM SAFETY AND EFFICACY 50
7 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE 51
7.1 OVERVIEW 52
7.2 VIRAL VECTOR 55
7.2.1 ADENOVIRUS 56
7.2.2 RETROVIRUS 56
7.2.3 LENTIVIRUS 56
7.2.4 ADENO-ASSOCIATED VIRUS 56
7.2.5 VACCINIA VIRUS 56
7.2.6 HERPES SIMPLEX VIRUS 56
7.2.7 OTHERS 56
7.3 NON-VIRAL VECTOR 56
7.3.1 LIPOFECTION 57
7.3.2 INJECTION OF NAKED DNA 57
8 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD 58
8.1 OVERVIEW 59
8.2 EX-VIVO 62
8.3 IN-VIVO 62
9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION 64
9.1 OVERVIEW 65
9.2 ONCOLOGICAL DISORDERS 68
9.3 CARDIOVASCULAR DISEASES 68
9.4 INFECTIOUS DISEASES 69
9.5 RARE DISEASES 70
9.6 NUEROLOGICAL DISORDERS 71
9.7 OTHER DISEASES 72
10 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER 73
10.1 OVERVIEW 74
10.2 CANCER INSTITUTES 77
10.3 HOSPITALS 77
10.4 RESEARCH INSTITUTES 78
10.5 OTHERS 79
11 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY REGION 80
11.1 MIDDLE EAST AND AFRICA 81
11.1.1 SOUTH AFRICA 87
11.1.2 REST OF MIDDLE EAST AND AFRICA 89
12 MIDDLE EAST & AFRICA GENE THERAPY MARKET, COMPANY LANDSCAPE 90
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 90
13 COMPANY PROFILES 91
13.1 BIOGEN 91
13.1.1 COMPANY SNAPSHOT 91
13.1.2 REVENUE ANALYSIS 91
13.1.3 COMPANY SHARE ANALYSIS 92
13.1.4 SWOT ANALYSIS 92
13.1.5 PRODUCT PORTFOLIO 93
13.1.6 RECENT DEVELOPMENT 93
13.2 KITE PHARMA 94
13.2.1 COMPANY SNAPSHOT 94
13.2.2 REVENUE ANALYSIS 94
13.2.3 COMPANY SHARE ANALYSIS 95
13.2.4 SWOT ANALYSIS 95
13.2.5 PRODUCT PORTFOLIO 96
13.2.6 RECENT DEVELOPMENT 96
13.3 NOVARTIS AG 97
13.3.1 COMPANY SNAPSHOT 97
13.3.2 REVENUE ANALYSIS 97
13.3.3 COMPANY SHARE ANALYSIS 98
13.3.4 SWOT ANALYSIS 98
13.3.5 PRODUCT PORTFOLIO 99
13.3.6 RECENT DEVELOPMENTS 99
13.4 BRISTOL-MYERS SQUIBB COMPANY. 100
13.4.1 COMPANY SNAPSHOT 100
13.4.2 REVENUE ANALYSIS 100
13.4.3 COMPANY SHARE ANALYSIS 101
13.4.4 SWOT ANALYSIS 101
13.4.5 PRODUCT PORTFOLIO 102
13.4.6 RECENT DEVELOPMENT 102
13.5 OXFORD BIOMEDICA 103
13.5.1 COMPANY SNAPSHOT 103
13.5.2 REVENUE ANALYSIS 103
13.5.3 COMPANY SHARE ANALYSIS 104
13.5.4 SWOT ANALYSIS 104
13.5.5 PRODUCT PORTFOLIO 105
13.5.6 RECENT DEVELOPMENTS 105
13.6 AGC BIOLOGICS 106
13.6.1 COMPANY SNAPSHOT 106
13.6.2 PRODUCT PORTFOLIO 106
13.6.3 RECENT DEVELOPMENT 106
13.7 ANGES, INC 107
13.7.1 COMPANY SNAPSHOT 107
13.7.2 REVENUE ANALYSIS 107
13.7.3 PRODUCT PORTFOLIO 108
13.7.4 RECENT DEVELOPMENT 108
13.8 AMGEN INC. 109
13.8.1 COMPANY SNAPSHOT 109
13.8.2 REVENUE ANALYSIS 109
13.8.3 PRODUCT PORTFOLIO 110
13.8.4 RECENT DEVELOPMENT 110
13.9 BLUEBIRD BIO, INC. 111
13.9.1 COMPANY SNAPSHOT 111
13.9.2 PRODUCT PORTFOLIO 111
13.9.3 RECENT DEVELOPMENT 111
13.10 CHIESI FARMACEUTICI S.P.A 112
13.10.1 COMPANY SNAPSHOT 112
13.10.2 REVENUE ANALYSIS 112
13.10.3 PRODUCT PORTFOLIO 113
13.10.4 RECENT DEVELOPMENT 113
13.11 DENDREON PHARMACEUTICALS LLC 114
13.11.1 COMPANY SNAPSHOT 114
13.11.2 PRODUCT PORTFOLIO 114
13.11.3 RECENT DEVELOPMENT 114
13.12 ENZYVANT THERAPEUTICS GMBH 115
13.12.1 COMPANY SNAPSHOT 115
13.12.2 RODUCT PORTFOLIO 115
13.12.3 RECENT DEVELOPMENT 115
13.13 FERRING B.V. 116
13.13.1 COMPANY SNAPSHOT 116
13.13.2 PRODUCT PORTFOLIO 116
13.13.3 RECENT DEVELOPMENT 116
13.14 JANSSEN PHARMACEUTICALS, INC. 117
13.14.1 COMPANY SNAPSHOT 117
13.14.2 PRODUCT PORTFOLIO 117
13.14.3 RECENT DEVELOPMENT 117
13.15 MALLINCKRODT. 118
13.15.1 COMPANY SNAPSHOT 118
13.15.2 REVENUE ANALYSIS 118
13.15.3 PRODUCT PORTFOLIO 119
13.15.4 RECENT DEVELOPMENT 119
13.16 ORCHARD THERAPEUTICS PLC. 120
13.16.1 COMPANY SNAPSHOT 120
13.16.2 REVENUE ANALYSIS 120
13.16.3 PRODUCT PORTFOLIO 121
13.16.4 RECENT DEVELOPMENT 121
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD. 122
13.17.1 COMPANY SNAPSHOT 122
13.17.2 PRODUCT PORTFOLIO 122
13.17.3 RECENT DEVELOPMENT 122
13.18 SIBONO 123
13.18.1 COMPANY SNAPSHOT 123
13.18.2 PRODUCT PORTFOLIO 123
13.18.3 RECENT DEVELOPMENT 123
13.19 SPARK THERAPEUTICS, INC. 124
13.19.1 COMPANY SNAPSHOT 124
13.19.2 PRODUCT PORTFOLIO 124
13.19.3 RECENT DEVELOPMENT 124
13.20 UNIQURE NV. 125
13.20.1 COMPANY SNAPSHOT 125
13.20.2 REVENUE ANALYSIS 125
13.20.3 PRODUCT PORTFOLIO 126
13.20.4 RECENT DEVELOPMENT 126
14 QUESTIONNAIRE 127
15 RELATED REPORTS 130

ページTOPに戻る



図表リスト

LIST OF TABLES
TABLE 1 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 47
TABLE 2 MIDDLE EAST & AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 48
TABLE 3 MIDDLE EAST & AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 48
TABLE 4 MIDDLE EAST & AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 50
TABLE 5 MIDDLE EAST & AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 50
TABLE 6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 54
TABLE 7 MIDDLE EAST & AFRICA EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 55
TABLE 8 MIDDLE EAST & AFRICA IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 56
TABLE 9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 60
TABLE 10 MIDDLE EAST & AFRICA ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 11 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 62
TABLE 12 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 63
TABLE 13 MIDDLE EAST & AFRICA RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 14 MIDDLE EAST & AFRICA NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 15 MIDDLE EAST & AFRICA OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 16 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 69
TABLE 17 MIDDLE EAST & AFRICA CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 19 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 20 MIDDLE EAST & AFRICA OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 21 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 78
TABLE 22 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 78
TABLE 23 MIDDLE EAST AND AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 78
TABLE 24 MIDDLE EAST AND AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 78
TABLE 25 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 79
TABLE 26 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 79
TABLE 27 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 79
TABLE 28 SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 80
TABLE 29 SOUTH AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 80
TABLE 30 SOUTH AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 80
TABLE 31 SOUTH AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 80
TABLE 32 SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 81
TABLE 33 SOUTH AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 81
TABLE 34 REST OF MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 82

　

ページTOPに戻る


　

Summary

Middle East and Africa gene therapy market is projected to register a CAGR of 18.3% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Middle East and Africa Gene Therapy Market, By Vector Type (Viral Vector and Non-viral Vector), Method (Ex-vivo and In-vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research institutes, and Others), Country (South Africa and Rest of Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the gene therapy market are:

• Rising demand of personalized medicine
• Rising prevalence of genetic disorders
• Novel approaches of gene therapy

Market Players:

The key market players for Middle East and Africa gene therapy market are listed below:

• Amgen, Inc.
• AnGes, Inc
• Biogen
• Bristol Myers Squibb Company
• CHIESI Farmaceutici S.p.A.
• Janssen Pharmaceuticals, Inc.
• Novartis AG




ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET 20
1.4 CURRENCY AND PRICING 22
1.5 LIMITATIONS 22
1.6 MARKETS COVERED 22
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.6 MULTIVARIATE MODELLING 31
2.7 MARKET END USER COVERAGE GRID 31
2.8 PRODUCT LIFELINE CURVE 32
2.9 DBMR MARKET POSITION GRID 33
2.10 VENDOR SHARE ANALYSIS 34
2.11 SECONDARY SOURCES 35
2.12 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 39
4.1 PESTEL ANALYSIS 40
4.2 PORTER FIVE ANALYSIS 41
5 UPDATE ON GERMLINE GENE THERAPY 42
5.1 GERMLINE GENE THERAPY 42
6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, MO 43
6.1 DRIVERS 45
6.1.1 NOVEL APPROACHES TO GENE THERAPY 45
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 45
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 46
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 47
6.2 RESTRAINTS 47
6.2.1 HIGH COST OF GENE THERAPY 47
6.2.2 ETHICAL AND SAFETY CONCERNS 48
6.2.3 COMPLEXITY OF GENE THERAPY 48
6.3 OPPORTUNITIES 49
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 49
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 49
6.4 CHALLENGES 50
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 50
6.4.2 LONG-TERM SAFETY AND EFFICACY 50
7 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE 51
7.1 OVERVIEW 52
7.2 VIRAL VECTOR 55
7.2.1 ADENOVIRUS 56
7.2.2 RETROVIRUS 56
7.2.3 LENTIVIRUS 56
7.2.4 ADENO-ASSOCIATED VIRUS 56
7.2.5 VACCINIA VIRUS 56
7.2.6 HERPES SIMPLEX VIRUS 56
7.2.7 OTHERS 56
7.3 NON-VIRAL VECTOR 56
7.3.1 LIPOFECTION 57
7.3.2 INJECTION OF NAKED DNA 57
8 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD 58
8.1 OVERVIEW 59
8.2 EX-VIVO 62
8.3 IN-VIVO 62
9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION 64
9.1 OVERVIEW 65
9.2 ONCOLOGICAL DISORDERS 68
9.3 CARDIOVASCULAR DISEASES 68
9.4 INFECTIOUS DISEASES 69
9.5 RARE DISEASES 70
9.6 NUEROLOGICAL DISORDERS 71
9.7 OTHER DISEASES 72
10 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER 73
10.1 OVERVIEW 74
10.2 CANCER INSTITUTES 77
10.3 HOSPITALS 77
10.4 RESEARCH INSTITUTES 78
10.5 OTHERS 79
11 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY REGION 80
11.1 MIDDLE EAST AND AFRICA 81
11.1.1 SOUTH AFRICA 87
11.1.2 REST OF MIDDLE EAST AND AFRICA 89
12 MIDDLE EAST & AFRICA GENE THERAPY MARKET, COMPANY LANDSCAPE 90
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 90
13 COMPANY PROFILES 91
13.1 BIOGEN 91
13.1.1 COMPANY SNAPSHOT 91
13.1.2 REVENUE ANALYSIS 91
13.1.3 COMPANY SHARE ANALYSIS 92
13.1.4 SWOT ANALYSIS 92
13.1.5 PRODUCT PORTFOLIO 93
13.1.6 RECENT DEVELOPMENT 93
13.2 KITE PHARMA 94
13.2.1 COMPANY SNAPSHOT 94
13.2.2 REVENUE ANALYSIS 94
13.2.3 COMPANY SHARE ANALYSIS 95
13.2.4 SWOT ANALYSIS 95
13.2.5 PRODUCT PORTFOLIO 96
13.2.6 RECENT DEVELOPMENT 96
13.3 NOVARTIS AG 97
13.3.1 COMPANY SNAPSHOT 97
13.3.2 REVENUE ANALYSIS 97
13.3.3 COMPANY SHARE ANALYSIS 98
13.3.4 SWOT ANALYSIS 98
13.3.5 PRODUCT PORTFOLIO 99
13.3.6 RECENT DEVELOPMENTS 99
13.4 BRISTOL-MYERS SQUIBB COMPANY. 100
13.4.1 COMPANY SNAPSHOT 100
13.4.2 REVENUE ANALYSIS 100
13.4.3 COMPANY SHARE ANALYSIS 101
13.4.4 SWOT ANALYSIS 101
13.4.5 PRODUCT PORTFOLIO 102
13.4.6 RECENT DEVELOPMENT 102
13.5 OXFORD BIOMEDICA 103
13.5.1 COMPANY SNAPSHOT 103
13.5.2 REVENUE ANALYSIS 103
13.5.3 COMPANY SHARE ANALYSIS 104
13.5.4 SWOT ANALYSIS 104
13.5.5 PRODUCT PORTFOLIO 105
13.5.6 RECENT DEVELOPMENTS 105
13.6 AGC BIOLOGICS 106
13.6.1 COMPANY SNAPSHOT 106
13.6.2 PRODUCT PORTFOLIO 106
13.6.3 RECENT DEVELOPMENT 106
13.7 ANGES, INC 107
13.7.1 COMPANY SNAPSHOT 107
13.7.2 REVENUE ANALYSIS 107
13.7.3 PRODUCT PORTFOLIO 108
13.7.4 RECENT DEVELOPMENT 108
13.8 AMGEN INC. 109
13.8.1 COMPANY SNAPSHOT 109
13.8.2 REVENUE ANALYSIS 109
13.8.3 PRODUCT PORTFOLIO 110
13.8.4 RECENT DEVELOPMENT 110
13.9 BLUEBIRD BIO, INC. 111
13.9.1 COMPANY SNAPSHOT 111
13.9.2 PRODUCT PORTFOLIO 111
13.9.3 RECENT DEVELOPMENT 111
13.10 CHIESI FARMACEUTICI S.P.A 112
13.10.1 COMPANY SNAPSHOT 112
13.10.2 REVENUE ANALYSIS 112
13.10.3 PRODUCT PORTFOLIO 113
13.10.4 RECENT DEVELOPMENT 113
13.11 DENDREON PHARMACEUTICALS LLC 114
13.11.1 COMPANY SNAPSHOT 114
13.11.2 PRODUCT PORTFOLIO 114
13.11.3 RECENT DEVELOPMENT 114
13.12 ENZYVANT THERAPEUTICS GMBH 115
13.12.1 COMPANY SNAPSHOT 115
13.12.2 RODUCT PORTFOLIO 115
13.12.3 RECENT DEVELOPMENT 115
13.13 FERRING B.V. 116
13.13.1 COMPANY SNAPSHOT 116
13.13.2 PRODUCT PORTFOLIO 116
13.13.3 RECENT DEVELOPMENT 116
13.14 JANSSEN PHARMACEUTICALS, INC. 117
13.14.1 COMPANY SNAPSHOT 117
13.14.2 PRODUCT PORTFOLIO 117
13.14.3 RECENT DEVELOPMENT 117
13.15 MALLINCKRODT. 118
13.15.1 COMPANY SNAPSHOT 118
13.15.2 REVENUE ANALYSIS 118
13.15.3 PRODUCT PORTFOLIO 119
13.15.4 RECENT DEVELOPMENT 119
13.16 ORCHARD THERAPEUTICS PLC. 120
13.16.1 COMPANY SNAPSHOT 120
13.16.2 REVENUE ANALYSIS 120
13.16.3 PRODUCT PORTFOLIO 121
13.16.4 RECENT DEVELOPMENT 121
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD. 122
13.17.1 COMPANY SNAPSHOT 122
13.17.2 PRODUCT PORTFOLIO 122
13.17.3 RECENT DEVELOPMENT 122
13.18 SIBONO 123
13.18.1 COMPANY SNAPSHOT 123
13.18.2 PRODUCT PORTFOLIO 123
13.18.3 RECENT DEVELOPMENT 123
13.19 SPARK THERAPEUTICS, INC. 124
13.19.1 COMPANY SNAPSHOT 124
13.19.2 PRODUCT PORTFOLIO 124
13.19.3 RECENT DEVELOPMENT 124
13.20 UNIQURE NV. 125
13.20.1 COMPANY SNAPSHOT 125
13.20.2 REVENUE ANALYSIS 125
13.20.3 PRODUCT PORTFOLIO 126
13.20.4 RECENT DEVELOPMENT 126
14 QUESTIONNAIRE 127
15 RELATED REPORTS 130

ページTOPに戻る



List of Tables/Graphs

LIST OF TABLES
TABLE 1 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 47
TABLE 2 MIDDLE EAST & AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 48
TABLE 3 MIDDLE EAST & AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 48
TABLE 4 MIDDLE EAST & AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 50
TABLE 5 MIDDLE EAST & AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 50
TABLE 6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 54
TABLE 7 MIDDLE EAST & AFRICA EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 55
TABLE 8 MIDDLE EAST & AFRICA IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 56
TABLE 9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 60
TABLE 10 MIDDLE EAST & AFRICA ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 11 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 62
TABLE 12 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 63
TABLE 13 MIDDLE EAST & AFRICA RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 14 MIDDLE EAST & AFRICA NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 15 MIDDLE EAST & AFRICA OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 16 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 69
TABLE 17 MIDDLE EAST & AFRICA CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 19 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 20 MIDDLE EAST & AFRICA OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 21 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 78
TABLE 22 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 78
TABLE 23 MIDDLE EAST AND AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 78
TABLE 24 MIDDLE EAST AND AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 78
TABLE 25 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 79
TABLE 26 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 79
TABLE 27 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 79
TABLE 28 SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 80
TABLE 29 SOUTH AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 80
TABLE 30 SOUTH AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 80
TABLE 31 SOUTH AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 80
TABLE 32 SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 81
TABLE 33 SOUTH AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 81
TABLE 34 REST OF MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 82

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（電池）の最新刊レポート

Data Bridge Market Research 社の最新刊レポート

本レポートと同じKEY WORD（gene）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/10/01　10:26

145.10 円

161.88 円

196.72 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.